• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同离心方案对血浆游离 DNA 中 EGFR 基因突变检测的影响。

Effects of Different Centrifugation Protocols on the Detection of EGFR Mutations in Plasma Cell-Free DNA.

机构信息

Department of Laboratory Medicine, Busan, South Korea.

Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.

出版信息

Am J Clin Pathol. 2022 Aug 4;158(2):206-211. doi: 10.1093/ajcp/aqac024.

DOI:10.1093/ajcp/aqac024
PMID:35285877
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9350828/
Abstract

OBJECTIVES

Various preanalytical factors, including the collection tube, storage conditions, and centrifugation, affect the detection results of plasma cell-free DNA (cfDNA). We compared the effect of different centrifugation protocols on the detection of EGFR mutations in cfDNA.

METHODS

We analyzed 117 plasma specimens from 110 patients with non-small cell lung cancer using the cobas EGFR Mutation Test v2 (Roche Diagnostics). We compared the identified EGFR mutations and semiquantitative index values from the 1- and 2-step centrifugation groups and confirmed the clinical impact of differences in the results after further high-speed centrifugation.

RESULTS

We detected EGFR mutations in 44 (37.6%) and 47 (40.2%) samples that were centrifuged once and twice, respectively; the 2 groups showed an 89.7% (105/117) concordance and a strong correlation in their semiquantitative index values (r = 0.929). Among the 12 inconsistent result pairs, 9 samples of 2-step centrifugation (75%) were consistent with the results of a recent tissue biopsy.

CONCLUSIONS

Additional high-speed centrifugation has been shown to increase the sensitivity of EGFR mutation detection in a commercial in vitro diagnostic real-time polymerase chain reaction device and is an optimal preanalytical factor for detecting low-allele frequency gene mutations using low concentrations of cfDNA.

摘要

目的

多种分析前因素,包括采集管、储存条件和离心,都会影响血浆游离循环 DNA(cfDNA)的检测结果。我们比较了不同离心方案对 cfDNA 中 EGFR 突变检测的影响。

方法

我们使用 cobas EGFR Mutation Test v2(罗氏诊断)分析了 110 例非小细胞肺癌患者的 117 份血浆样本。我们比较了 1 步和 2 步离心组鉴定的 EGFR 突变和半定量指数值,并在进一步高速离心后确认了结果差异的临床影响。

结果

我们在分别经 1 次和 2 次离心的样本中检测到 EGFR 突变,分别为 44(37.6%)和 47(40.2%);2 组的一致性为 89.7%(105/117),半定量指数值相关性很强(r=0.929)。在 12 对不一致的结果中,2 步离心的 9 个样本(75%)与最近的组织活检结果一致。

结论

进一步高速离心可提高商业体外诊断实时聚合酶链反应设备中 EGFR 突变检测的灵敏度,是检测低浓度 cfDNA 中低等位基因频率基因突变的最佳分析前因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9570/9350828/32dff9852968/aqac024f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9570/9350828/37fe3f094357/aqac024f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9570/9350828/32dff9852968/aqac024f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9570/9350828/37fe3f094357/aqac024f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9570/9350828/32dff9852968/aqac024f0002.jpg

相似文献

1
Effects of Different Centrifugation Protocols on the Detection of EGFR Mutations in Plasma Cell-Free DNA.不同离心方案对血浆游离 DNA 中 EGFR 基因突变检测的影响。
Am J Clin Pathol. 2022 Aug 4;158(2):206-211. doi: 10.1093/ajcp/aqac024.
2
Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.使用等位基因特异性定量PCR检测液体活检样本中的EGFR突变:两种常用诊断系统的真实世界比较评估。
Adv Med Sci. 2021 Sep;66(2):336-342. doi: 10.1016/j.advms.2021.06.003. Epub 2021 Jul 15.
3
Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubes.基于聚合酶链反应的检测方法在使用无细胞 DNA 采集管的非小细胞肺癌患者血浆游离 DNA 中检测 EGFR 突变的性能特征。
PLoS One. 2024 Apr 9;19(4):e0295987. doi: 10.1371/journal.pone.0295987. eCollection 2024.
4
Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non-small cell lung cancer specimens.从包含游离 DNA 的上清液和细针穿刺非小细胞肺癌标本的细胞沉淀中检测和比较 EGFR 突变。
Cancer Cytopathol. 2020 Aug;128(8):545-552. doi: 10.1002/cncy.22273. Epub 2020 Apr 14.
5
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.罗氏 cobas® EGFR 突变检测 v2 用于非小细胞肺癌的简介。
Expert Rev Mol Diagn. 2017 Mar;17(3):209-215. doi: 10.1080/14737159.2017.1288568. Epub 2017 Feb 9.
6
The Dynamic Use of Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients.在非小细胞肺癌患者的不同治疗线中,作为一种随访生物标志物,游离 DNA 中的突变分析的动态应用。
Dis Markers. 2019 Jan 23;2019:7954921. doi: 10.1155/2019/7954921. eCollection 2019.
7
Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma Mutations.Oncomine Lung cfDNA 分析性能评估:检测血浆基因突变。
Genes (Basel). 2023 Jun 2;14(6):1219. doi: 10.3390/genes14061219.
8
Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma.利用 SuperARMS EGFR 突变检测试剂盒检测肺腺癌患者血浆无细胞 DNA 中的 EGFR。
Clin Lung Cancer. 2018 May;19(3):e313-e322. doi: 10.1016/j.cllc.2017.12.009. Epub 2017 Dec 21.
9
Detection of Loss of Heterozygosity in cfDNA of Advanced - or -Mutated Non-Small-Cell Lung Cancer Patients.晚期或突变型非小细胞肺癌患者 cfDNA 杂合性缺失的检测。
Int J Mol Sci. 2019 Dec 20;21(1):66. doi: 10.3390/ijms21010066.
10
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.AURA3 试验中外周血和组织标本中表皮生长因子受体突变分析:奥希替尼对比培美曲塞/顺铂用于 T790M 突变阳性的晚期非小细胞肺癌。
Cancer. 2020 Jan 15;126(2):373-380. doi: 10.1002/cncr.32503. Epub 2019 Nov 26.

引用本文的文献

1
Comparison of tissue-based and plasma-based testing for EGFR mutation in non-small cell lung cancer patients.非小细胞肺癌患者中基于组织和基于血浆的表皮生长因子受体(EGFR)突变检测的比较
J Pathol Transl Med. 2025 Jan;59(1):60-67. doi: 10.4132/jptm.2024.10.01. Epub 2025 Jan 15.
2
The impact of preanalytical variables on the analysis of cell-free DNA from blood and urine samples.分析前变量对血液和尿液样本中游离DNA分析的影响。
Front Cell Dev Biol. 2024 May 9;12:1385041. doi: 10.3389/fcell.2024.1385041. eCollection 2024.
3
Pre-Analytical Factors Affecting Extracellular DNA in Saliva.

本文引用的文献

1
Analytical Validation of a Pan-Cancer Panel for Cell-Free Assay for the Detection of Mutations.用于检测突变的无细胞分析泛癌检测板的分析验证
Diagnostics (Basel). 2021 Jun 2;11(6):1022. doi: 10.3390/diagnostics11061022.
2
Detection of the G719S Mutation in Non-small Cell Lung Cancer Using Droplet Digital PCR.使用液滴数字PCR检测非小细胞肺癌中的G719S突变
Front Med (Lausanne). 2020 Nov 13;7:594900. doi: 10.3389/fmed.2020.594900. eCollection 2020.
3
Comparison of cobas Mutation Test v2 and PANAMutyper-R- for Detection and Semi-Quantification of Epidermal Growth Factor Receptor Mutations in Plasma and Pleural Effusion Supernatant.
影响唾液中细胞外DNA的分析前因素。
Diagnostics (Basel). 2024 Jan 24;14(3):249. doi: 10.3390/diagnostics14030249.
4
Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study.液体活检检测阿法替尼治疗非小细胞肺癌患者表皮生长因子受体突变:一项多中心前瞻性研究。
BMC Cancer. 2022 Oct 4;22(1):1035. doi: 10.1186/s12885-022-10135-z.
cobas Mutation Test v2 与 PANAMutyper-R- 在检测和半定量血浆和胸腔积液上清液中表皮生长因子受体突变中的比较。
Ann Lab Med. 2019 Sep;39(5):478-487. doi: 10.3343/alm.2019.39.5.478.
4
Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol.循环游离DNA和RNA分析作为液体活检:最佳离心方案
Cancers (Basel). 2019 Mar 30;11(4):458. doi: 10.3390/cancers11040458.
5
The Dynamic Use of Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients.在非小细胞肺癌患者的不同治疗线中,作为一种随访生物标志物,游离 DNA 中的突变分析的动态应用。
Dis Markers. 2019 Jan 23;2019:7954921. doi: 10.1155/2019/7954921. eCollection 2019.
6
Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows-Venous Whole Blood and Plasma.用于标准化分析前工作流程的液体活检保存解决方案——静脉全血和血浆
Curr Pathobiol Rep. 2018;6(4):275-286. doi: 10.1007/s40139-018-0180-z. Epub 2018 Oct 18.
7
Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.表皮生长因子受体突变阳性非小细胞肺癌中的肿瘤克隆性和耐药机制:对治疗顺序的影响。
Future Oncol. 2019 Feb;15(6):637-652. doi: 10.2217/fon-2018-0736. Epub 2018 Nov 8.
8
First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.106 例复合 EGFR 突变肺癌患者的第一代 EGFR 酪氨酸激酶抑制剂治疗:单中心临床实践经验。
Cancer Commun (Lond). 2018 Jul 28;38(1):51. doi: 10.1186/s40880-018-0321-0.
9
A Comparative Study for Detection of Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories.血浆游离 DNA 中突变的检测在韩国临床诊断实验室的比较研究。
Biomed Res Int. 2018 May 8;2018:7392419. doi: 10.1155/2018/7392419. eCollection 2018.
10
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.晚期表皮生长因子受体(EGFR)突变型肺癌中共发基因改变的演变及其临床影响
Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6.